Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H14N2O2 |
Molecular Weight | 218.2518 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
InChI
InChIKey=DQMZLTXERSFNPB-UHFFFAOYSA-N
InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)
Molecular Formula | C12H14N2O2 |
Molecular Weight | 218.2518 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2871724
http://www.rxlist.com/mysoline-drug/side-effects-interactions.htm
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2871724
http://www.rxlist.com/mysoline-drug/side-effects-interactions.htm
Primidone is an anticonvulsant of the barbiturate class. It was introduced in 1954 under the brand name Mysoline by Wyeth in the United States. Mysoline, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. Mysoline raises electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. The mechanism(s) of primidone’s antiepileptic action is not known. Primidone per se has anticonvulsant activity, as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, PEMA potentiates the anticonvulsant activity of phenobarbital in experimental animals. Primidone itself doesn’t act on GABA-A receptors. It is active metabolite - phenobarbital primary acts via modulation of GABA -A receptors. The most frequently occurring early side effects are ataxia and vertigo. These tend to disappear with continued therapy, or with reduction of initial dosage. Occasionally, the following have been reported: nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, sexual impotency, diplopia, nystagmus, drowsiness, and morbilliform skin eruptions.Granulocytopenia, agranulocytosis, and red-cell hypoplasia and aplasia, have been reported rarely. These and, occasionally, other persistant or severe side effects may necessitate withdrawal of the drug. Megaloblastic anemia may occur as a rare idiosyncrasy to Mysoline and to other anticonvulsants. The anemia responds to folic acid without necessity of discontinuing medication.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13359420
Curator's Comment: The effectiveness of primidone was demonstrated by Yule Bogue in the Imperial Chemical Industries' Laboratories in 1949 and the results published in 1953.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=2871724 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MYSOLINE Approved UseMysoline, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. Launch Date1954 |
|||
Primary | MYSOLINE Approved UseMysoline, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. Launch Date1954 |
|||
Primary | MYSOLINE Approved UseMysoline, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. Launch Date1954 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.45 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9688064 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMIDONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
140.5 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9688064 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMIDONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9688064 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMIDONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
62.5 mg 1 times / day multiple, oral Studied dose Dose: 62.5 mg, 1 times / day Route: oral Route: multiple Dose: 62.5 mg, 1 times / day Sources: |
unhealthy, 18-83 |
Disc. AE: Nausea, Ataxia... AEs leading to discontinuation/dose reduction: Nausea (acute) Sources: Ataxia (acute) Dizziness (acute) Confusion (acute) |
15 mg single, oral Overdose |
healthy, 34 |
Disc. AE: Coma, Crystalluria... AEs leading to discontinuation/dose reduction: Coma Sources: Crystalluria |
500 mg 4 times / day multiple, oral Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Suicidal behavior, Suicidal ideation... AEs leading to discontinuation/dose reduction: Suicidal behavior Sources: Suicidal ideation |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ataxia | acute Disc. AE |
62.5 mg 1 times / day multiple, oral Studied dose Dose: 62.5 mg, 1 times / day Route: oral Route: multiple Dose: 62.5 mg, 1 times / day Sources: |
unhealthy, 18-83 |
Confusion | acute Disc. AE |
62.5 mg 1 times / day multiple, oral Studied dose Dose: 62.5 mg, 1 times / day Route: oral Route: multiple Dose: 62.5 mg, 1 times / day Sources: |
unhealthy, 18-83 |
Dizziness | acute Disc. AE |
62.5 mg 1 times / day multiple, oral Studied dose Dose: 62.5 mg, 1 times / day Route: oral Route: multiple Dose: 62.5 mg, 1 times / day Sources: |
unhealthy, 18-83 |
Nausea | acute Disc. AE |
62.5 mg 1 times / day multiple, oral Studied dose Dose: 62.5 mg, 1 times / day Route: oral Route: multiple Dose: 62.5 mg, 1 times / day Sources: |
unhealthy, 18-83 |
Coma | Disc. AE | 15 mg single, oral Overdose |
healthy, 34 |
Crystalluria | Disc. AE | 15 mg single, oral Overdose |
healthy, 34 |
Suicidal behavior | Disc. AE | 500 mg 4 times / day multiple, oral Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Suicidal ideation | Disc. AE | 500 mg 4 times / day multiple, oral Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no | ||||
no | ||||
no | ||||
no | ||||
unlikely | ||||
weak | ||||
yes [Activation 39.81072 uM] | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/29955442/ |
yes | |||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/ |
yes | |||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29955442/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/29955442/ |
yes | |||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/ |
yes | |||
yes | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29955442/ |
yes | |||
yes | yes (co-administration study) Comment: The mean serum concentration of carbamazepine is lower when the drug is given in combination with primidone (58·2%) than when carbamazepine is given alone (100%). |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
major | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Prediction of adsorption from multicomponent solutions by activated carbon using single-solute parameters. Part II--Proposed equation. | 2002 |
|
Fate of pharmaceuticals during indirect potable reuse. | 2002 |
|
Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. | 2002 |
|
Ecological data of Travassosnema travassosi travassosi (Dracunculoidea: Guyanemidae) from the humour of the eyes of Acestrorhynchus lacustris from Tibagi River, Paraná, Brazil. | 2002 Jan |
|
Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. | 2002 Jan |
|
Management of essential tremor. | 2002 Jul |
|
Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. | 2002 Jun |
|
Some common issues in the use of antiepileptic drugs. | 2002 Mar |
|
Randomized trial comparing primidone initiation schedules for treating essential tremor. | 2002 Mar |
|
Anticonvulsant hypersensitivity syndrome. | 2002 Mar-Apr |
|
Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. | 2002 May 10 |
|
Primary standardization of assays for anticonvulsant drugs: comparison of accuracy and precision. | 2002 Nov |
|
QT length and heart function in primidone hypocalcaemia. | 2002 Oct |
|
Benefits and risks of pharmacological treatments for essential tremor. | 2003 |
|
Effects of barbiturates on human platelet aggregation differ depending on their chemical structures. | 2003 Aug |
|
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. | 2003 Aug |
|
Tremor. | 2003 Aug |
|
Essential tremor: differential diagnosis and current therapy. | 2003 Aug 1 |
|
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. | 2003 Jun |
|
Orthostatic tremor: report of a case and review of the literature. | 2003 Mar |
|
Clinical features, assessment and treatment of essential tremor. | 2003 Mar |
|
Tremor--easily seen but difficult to describe and treat. | 2003 Mar |
|
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? | 2003 May |
|
AstraZeneca postpones discontinuation of Mysoline. | 2003 Oct |
|
Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. | 2003 Oct |
|
Therapeutic drug monitoring of old and newer anti-epileptic drugs. | 2004 |
|
Key structural features of ligands for activation of human pregnane X receptor. | 2004 Apr |
|
Fatal mix-up between prednisone and primidone. | 2004 Aug 1 |
|
When breastfeeding mothers need CNS-acting drugs. | 2004 Fall |
|
Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. | 2004 Jul |
|
Spectrum of epilepsy in tuberous sclerosis. | 2004 Jun |
|
Antiepileptic drugs: indications other than epilepsy. | 2004 Jun |
|
Fracture risk associated with use of antiepileptic drugs. | 2004 Nov |
|
Initial treatment of epilepsy: special issues in treating the elderly. | 2004 Nov 23 |
|
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. | 2004 Oct |
|
Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. | 2004 Oct |
|
Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. | 2004 Oct |
|
Discontinuation of Mysoline: lessons to be learned. | 2004 Oct 30-Nov 5 |
|
Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. | 2004 Sep |
|
[Hyperhomocysteinemia and treatment with antiepileptic drugs. Effects of different doses of folic acid]. | 2005 Apr 16 |
|
[Population pharmacokinetics of carbamazepine in adults with epilepsy]. | 2005 Jan-Feb |
|
Drug-induced hypersensitivity syndrome in a premature infant. | 2005 Jan-Feb |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Practice parameter: therapies for essential tremor [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology. | 2005 Jun 28 |
|
Pharmacological treatment of disabling tremor. | 2005 Mar |
|
Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. | 2005 Mar |
|
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. | 2005 Mar-Apr |
|
Primidone is associated with interictal depression in patients with epilepsy. | 2005 May |
|
Determination of levetiracetam in human plasma with minimal sample pretreatment. | 2005 May 5 |
|
Anticonvulsant activity and tolerance of ELB138 in dogs with epilepsy: a clinical pilot study. | 2006 Jul |
Sample Use Guides
Patients 8 years of age and older who have received no previous treatment may be started according to the following regimen using either 50 mg or scored 250 mg tablets:
Days 1 to 3: 100 to 125 mg at bedtime.
Days 4 to 6: 100 to 125 mg b.i.d.
Days 7 to 9: 100 to 125 mg t.i.d.
Day 10 to maintenance: 250 mg t.i.d.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:45:37 GMT 2025
by
admin
on
Mon Mar 31 17:45:37 GMT 2025
|
Record UNII |
13AFD7670Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN03AA03
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
NCI_THESAURUS |
C67084
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
WHO-ATC |
N03AA03
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
NDF-RT |
N0000008486
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
LIVERTOX |
NBK548512
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
CFR |
21 CFR 862.3680
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
NDF-RT |
N0000175753
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
||
|
CFR |
21 CFR 520.1900
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5338
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
DTXSID7023510
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
DB00794
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
m9135
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | Merck Index | ||
|
41701
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
4909
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
8412
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
8691
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB10045MIG
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
204-737-0
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
13AFD7670Q
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
Primidone
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
CHEMBL856
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
100000081656
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
248
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
PRIMIDONE
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
125-33-7
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
2267
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
1562000
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
D011324
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
C47686
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
13AFD7670Q
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY | |||
|
3169
Created by
admin on Mon Mar 31 17:45:37 GMT 2025 , Edited by admin on Mon Mar 31 17:45:37 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INDUCER | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
Percent of dose excreted in urine as metabolite.
Primidone is converted in man to phenobarbitone.
AMOUNT EXCRETED
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
Population PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC |
|
||